FOLH1 and neoplasm: Here, we present findings from a prospective study of 100 mCRPC patients receiving <sup>177</sup>Lu-PSMA-617, using shotgun proteomics to profile plasma-derived extracellular vesicle (EV) proteins alongside PSMA-positive circulating tumor cell (CTC) enumeration.